Becton, Dickinson and Company (NYSE:BDX) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.

Becton, Dickinson and Company (NYSE:BDX) had its target price decreased by JPMorgan Chase & Co. from $190.00 to $175.00 in a research report issued to clients and investors on Tuesday,MarketScreener reports. The firm currently has a “neutral” rating on the medical instruments supplier’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 3.72% from the stock’s current price.

Several other research firms have also weighed in on BDX. Royal Bank Of Canada restated a “sector perform” rating on shares of Becton, Dickinson and Company in a report on Monday. Bank of America lifted their price objective on Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a “neutral” rating in a research note on Monday, January 5th. Wells Fargo & Company cut their price target on Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating for the company in a report on Tuesday. Citigroup initiated coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 3rd. They issued a “buy” rating and a $233.00 price target on the stock. Finally, Wall Street Zen lowered Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Five analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $201.75.

Becton, Dickinson and Company Stock Performance

Shares of BDX stock opened at $168.73 on Tuesday. Becton, Dickinson and Company has a fifty-two week low of $162.29 and a fifty-two week high of $235.34. The stock’s 50-day moving average is $200.14 and its two-hundred day moving average is $192.53. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.11 and a quick ratio of 0.64. The firm has a market cap of $48.07 billion, a P/E ratio of 29.00, a PEG ratio of 2.32 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating the consensus estimate of $2.81 by $0.10. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The company’s revenue for the quarter was up 1.6% on a year-over-year basis. During the same quarter last year, the firm earned $3.43 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback plan on Tuesday, January 27th that permits the company to repurchase $10.00 million in outstanding shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s board believes its shares are undervalued.

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of Becton, Dickinson and Company stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total value of $334,010.60. Following the completion of the sale, the executive vice president directly owned 12,095 shares in the company, valued at $2,509,228.70. This trade represents a 11.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 2,463 shares of company stock worth $501,530 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Crux Wealth Advisors raised its holdings in shares of Becton, Dickinson and Company by 0.8% in the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 49 shares during the last quarter. Larson Financial Group LLC raised its position in Becton, Dickinson and Company by 1.7% during the fourth quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after acquiring an additional 53 shares in the last quarter. Camelot Portfolios LLC grew its position in shares of Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after acquiring an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC increased its position in Becton, Dickinson and Company by 3.6% during the fourth quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock worth $309,000 after buying an additional 55 shares during the last quarter. Finally, Gilbert & Cook Inc. raised its stake in Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after acquiring an additional 56 shares during the period. 86.97% of the stock is owned by institutional investors and hedge funds.

More Becton, Dickinson and Company News

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Q1 results beat street estimates — adjusted EPS $2.91 vs. consensus ~ $2.81 and revenue ~$5.25B topped estimates; margins expanded even as y/y adjusted profit declined. BD Reports First Quarter Fiscal 2026 Financial Results
• Positive Sentiment: BD completed the combination of its Biosciences & Diagnostic Solutions business with Waters, executing a strategic portfolio simplification that comes with a planned $4B cash deployment for the newly positioned “New BD.” BD Completes Combination of Biosciences & Diagnostic Solutions Business with Waters Corporation
• Positive Sentiment: Insider activity showed bullish option/stock bets recently, which can signal management/insider confidence in the post-transaction path. Becton Dickinson Insiders Placed Bullish Bets
• Neutral Sentiment: New analyst coverage from Barclays: started coverage with an “Overweight” rating but set a $202 price target (below recent levels), reflecting mixed views on valuation post-transaction.
• Neutral Sentiment: Company provided FY2026 EPS guidance for the reorganized New BD (EPS $12.35–$12.65) and affirmed revenue growth guidance — the range reflects the accounting and structural effects of the spin-off and cash deployment plans. BD Outlines $12.35–$12.65 EPS Guidance for 2026
• Negative Sentiment: Management cut its annual profit forecast to reflect the sale/spin-off of the biosciences & diagnostics unit — that reduction materially lowers FY26 EPS vs. prior consensus and is the main driver of the negative market reaction. Becton Dickinson cuts annual profit forecast (Reuters)
• Negative Sentiment: Market reaction: shares fell after the print — investors focused on the lowered FY26 EPS outlook and the impact of the transaction, which overshadowed the underlying beat and margin improvement. Shares fall as guidance overshadows beat

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.